UCLA

Running trials

• Not yet recruiting

  Screening Cardiometabolic Opportunities Using Transformative Echocardiography Artificial Intelligence (SCOUT Echo-AI)

  NCT07216859· Source

• Not yet recruiting

  Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer

  NCT07101666· Phase 2· Source

• Recruiting

  A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

  NCT07361510· Phase 3· Source

• Recruiting

  A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

  NCT07061574· Phase 1/2· Source

• Recruiting

  Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)

  NCT07357519· Phase 1/2· Source

• Recruiting

  Coaching and Leadership in Autism Support Settings

  NCT07276750· Source

• Recruiting

  A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer

  NCT07321106· Phase 1· Source

• Recruiting

  CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer

  NCT07322094· Phase 1/2· Source

• Recruiting

  Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.

  NCT07217704· Phase 3· Source

• Active, not recruiting

  Actinium Therapy for Late-stage Aggressive Sarcomas

  NCT07156565· Phase 1· Source

• Recruiting

  Early Feasibility Study (EFS) Evaluating Percutaneous Repair of the Atrial Septum With a Novel PFO Occluder: The PROTEA-PFO Study

  NCT07172464· Source

• Recruiting

  A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

  NCT06919965· Phase 3· Source

• Recruiting

  Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

  NCT07154706· Phase 3· Source

• Recruiting

  A Study to Prevent Infantile Spasms Relapse

  NCT06819670· Phase 2· Source

• Recruiting

  A Study of Lorigerlimab in Participants With Advanced Solid Tumors

  NCT06730347· Phase 2· Source

• Recruiting

  Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

  NCT07080242· Phase 1· Source

• Recruiting

  Diagnostic Performance Study of the EMVision Emu™ Brain Scanner in the Detection of Intracranial Hemorrhage in Suspected Stroke Patients

  NCT06999122· Source

• Recruiting

  Deceased Donor Bladder or Combined Kidney-bladder Transplantation: a Phase 0 First-in-human Study

  NCT06337942· Source

• Recruiting

  Promoting Early Intervention Timing and Attention to Language

  NCT05853861· Source

• Recruiting

  Single Time Point Prediction as Earlier Diagnosis of Progressive Pulmonary Fibrosis

  NCT06162884· Source

• Active, not recruiting

  Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

  NCT06655896· Phase 2· Source

• Active, not recruiting

  Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

  NCT06625320· Phase 3· Source

• Recruiting

  Thiamine Intervention and Coronary Artery Bypass Grafting

  NCT06326996· Early phase 1· Source

• Active, not recruiting

  A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

  NCT06470048· Phase 2· Source

• Recruiting

  Tolerability of MDMA in Schizophrenia

  NCT05770375· Phase 1/2· Source

• Recruiting

  Type 2 Diabetes and Blood Brain Barrier Improvement

  NCT06322212· Early phase 1· Source

• Recruiting

  Impact of Prebiotics in Ulcerative Colitis

  NCT06495658· Source

• Active, not recruiting

  Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes

  NCT06267391· Source

• Active, not recruiting

  A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

  NCT06329401· Phase 2· Source

• Recruiting

  Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate CancEr

  NCT05948657· Source

• Active, not recruiting

  Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

  NCT05902169· Phase 3· Source

• Active, not recruiting

  A Study of ADRX-0706 in Select Advanced Solid Tumors

  NCT06036121· Phase 1· Source

• Recruiting

  Lupus Landmark Study: A Prospective Registry and Biorepository

  NCT05934149· Source

• Active, not recruiting

  Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease

  NCT05701358· Source

• Active, not recruiting

  A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors

  NCT05653882· Phase 1· Source

• Recruiting

  Delayed Immunological Tolerance in Patients With Well-functioning Pre-existing HLA-matched Kidney Transplants

  NCT05525507· Phase 1· Source

• Active, not recruiting

  A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer

  NCT05488314· Phase 1/2· Source

• Active, not recruiting

  A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich Ataxia

  NCT05515536· Phase 3· Source

• Active, not recruiting

  Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia

  NCT05384587· Phase 2· Source

• Active, not recruiting

  The Arteriovenous Vascular (AV) ACCESS Trial

  NCT04646226· Source

• Active, not recruiting

  A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT05242471· Phase 2· Source

• Recruiting

  GEMINI-NSCLC: NSCLC Biomarker Study

  NCT05236114· Source

• Recruiting

  Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

  NCT05320198· Phase 1/2· Source

• Active, not recruiting

  Digital Limited Interaction Efficacy Trial of LifeSkills Mobile to Reduce HIV Incidence in YTW

  NCT05018611· Source

• Recruiting

  CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

  NCT05143996· Phase 1/2· Source

• Recruiting

  A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

  NCT04929223· Phase 1· Source

• Recruiting

  A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

  NCT04913285· Phase 1· Source

• Active, not recruiting

  Boosting Language Outcomes of Minimally Verbal Children With ASD (BLOOM)

  NCT04218331· Source

• Active, not recruiting

  PRISM Intervention Study

  NCT03883139· Source

• Active, not recruiting

  Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

  NCT04656652· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer6 recruiting
• Bladder cancer3 recruiting
• Colorectal cancer3 recruiting
• Ovarian cancer3 recruiting
• Acute myeloid leukemia2 recruiting
• Autism2 recruiting
• Childhood cancers2 recruiting
• Epilepsy2 recruiting
• Gastric and esophageal cancer2 recruiting
• Myelodysplastic syndromes2 recruiting
• Prostate cancer2 recruiting
• Stroke2 recruiting
• Type 2 diabetes2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Chronic kidney disease1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Coronary artery disease1 recruiting
• Crohn's disease1 recruiting
• Endometrial cancer1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Head and neck cancer1 recruiting
• Hodgkin lymphoma1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Lupus (SLE)1 recruiting
• Melanoma1 recruiting
• Multiple myeloma1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Neuroendocrine tumours1 recruiting
• Pancreatic cancer1 recruiting
• Sarcoma1 recruiting
• Schizophrenia1 recruiting
• Type 1 diabetes1 recruiting
• Ulcerative colitis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Community Collaboration to Advance Racial/Ethnic Equity in CRC Screening

  NCT05714644· Source

• Completed

  A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis

  NCT05083182· Phase 3· Source

• Completed

  Phase 2 Study of DKN-01 in Colorectal Cancer

  NCT05480306· Phase 2· Source

• Completed

  Optimization of Prostate Biopsy - Micro-Ultrasound Versus MRI

  NCT05220501· Source

• Terminated

  A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma

  NCT05119335· Phase 1/2· Source

• Terminated

  Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

  NCT04935229· Phase 1· Source

• Completed

  Evaluating BOSCC and ELSA as Outcome Measures in the Context of a JASPER Intervention Trial

  NCT04146428· Source

• Completed

  A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck

  NCT04665843· Phase 2· Source

• Completed

  LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

  NCT04666688· Phase 1/2· Source

• Completed

  A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer

  NCT04619797· Phase 2/3· Source

• Completed

  UTECH: Machine Learning for HIV Prevention Among Substance Using GBMSM

  NCT04710901· Source

• Completed

  Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study

  NCT04266197· Phase 2· Source

• Terminated

  A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment

  NCT04338269· Phase 3· Source

• Completed

  Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies

  NCT04260698· Phase 3· Source

• Completed

  Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

  NCT03836209· Phase 2· Source

• Terminated

  Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

  NCT03926624· Phase 3· Source

• Completed

  I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).

  NCT03939689· Phase 2· Source

• Completed

  Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer

  NCT03941093· Phase 3· Source

• Completed

  Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency

  NCT03679598· Phase 2· Source

• Completed

  MIND: Artemis in the Removal of Intracerebral Hemorrhage

  NCT03342664· Source

• Completed

  Target Engagement and Response to Oxytocin

  NCT03245437· Phase 4· Source

• Completed

  AFPᶜ³³²T in Advanced HCC

  NCT03132792· Phase 1· Source

• Completed

  Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS

  NCT02730299· Phase 3· Source

• Completed

  A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in People Aged 16 to 40 With Friedreich's Ataxia

  NCT02255435· Phase 2· Source

• Completed

  Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme

  NCT01591577· Phase 2· Source

• Terminated

  Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD)

  NCT01247207· Phase 3· Source